Skip to main content
Top

22-09-2023 | Pyelonephritis | Case Report

A case of emphysematous pyelonephritis in an older man with poorly controlled type 2 diabetes mellitus

Authors: Mayuka Nishikawara, Makoto Harada, Daiki Yamazaki, Tetsuji Kakegawa, Koji Hashimoto, Yuji Kamijo

Published in: CEN Case Reports

Login to get access

Abstract

Emphysematous pyelonephritis (EPN) is a necrotizing bacterial infection characterized by gas retention and a poor prognosis. We present the case of a 75-year-old man who was diagnosed early with EPN and received multidisciplinary treatment. He had poorly controlled type 2 diabetes mellitus (DM) and chronic kidney disease (CKD), and was treated with oral hypoglycemic drugs, including a sodium–glucose co-transporter-2 inhibitor. He experienced the onset of back pain in the midsection of his back, tenderness in the costovertebral angle, and a high fever (> 39 °C), accompanied by tachycardia, hypotension, and tachypnea. The patient was diagnosed with pyelonephritis and septic shock. Immediate measures encompassing empirical antibiotic therapy, administration of noradrenaline, blood glucose regulation, and urethral catheterization were implemented. However, due to the persistent fever (> 38 °C) and lack of improvement in his condition, abdominal computed tomography (CT) was repeated on the fourth day. This revealed the presence of gas around the right kidney parenchyma, leading to a diagnosis of EPN that had evolved from acute pyelonephritis. Subsequently, percutaneous drainage of the right kidney parenchyma was performed. Subsequently, multidisciplinary treatment was continued, and his condition gradually improved. Clinicians should evaluate abdominal CT when acute pyelonephritis does not improve within a few days of antibiotic therapy. Disease progression from acute pyelonephritis to EPN should be considered in patients with DM and CKD.
Literature
1.
go back to reference Schainuck LI, Fouty R, Cutler RE. Emphysematous pyelonephritis. A new case and review of previous observations. Am J Med. 1968;44:134–9. CrossRefPubMed Schainuck LI, Fouty R, Cutler RE. Emphysematous pyelonephritis. A new case and review of previous observations. Am J Med. 1968;44:134–9. CrossRefPubMed
2.
go back to reference Olvera-Posada D, Armengod-Fischer G, Vázquez-Lavista LG, Maldonado-Ávila M, Rosas-Nava E, Manzanilla-García H, et al. Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology. 2014;83:1280–4. CrossRefPubMed Olvera-Posada D, Armengod-Fischer G, Vázquez-Lavista LG, Maldonado-Ávila M, Rosas-Nava E, Manzanilla-García H, et al. Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology. 2014;83:1280–4. CrossRefPubMed
3.
go back to reference Rahoui M, Ouanes Y, Chaker K, Bibi M, Dali KM, Sellami A, et al. Predictive factors for failure of conservative management in patients with emphysematous pyelonephritis. Ann Med Surg (Lond). 2022;78: 103930. PubMed Rahoui M, Ouanes Y, Chaker K, Bibi M, Dali KM, Sellami A, et al. Predictive factors for failure of conservative management in patients with emphysematous pyelonephritis. Ann Med Surg (Lond). 2022;78: 103930. PubMed
4.
go back to reference Japanese Association for Infectious Disease/Japanese Society of Chemotherapy; JAID/JSC Guide/Guidelines to Clinical Management of Infectious Disease Preparing Committee; Urinary tract infection/male genital infection working group, Shingo Y, Kiyohito I, Hiroshi H, Tadahiro N, Isao M, Tadashi H, et al. JAID/JSC Guidelines for clinical management of infectious disease 2015 - urinary tract infection/male genital infection. J Infect Chemother. 2017;23(11):733–51. CrossRef Japanese Association for Infectious Disease/Japanese Society of Chemotherapy; JAID/JSC Guide/Guidelines to Clinical Management of Infectious Disease Preparing Committee; Urinary tract infection/male genital infection working group, Shingo Y, Kiyohito I, Hiroshi H, Tadahiro N, Isao M, Tadashi H, et al. JAID/JSC Guidelines for clinical management of infectious disease 2015 - urinary tract infection/male genital infection. J Infect Chemother. 2017;23(11):733–51. CrossRef
5.
go back to reference Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160:797–805. CrossRefPubMed Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160:797–805. CrossRefPubMed
6.
go back to reference Ahlering TE, Boyd SD, Hamilton CL, Bragin SD, Chandrasoma PT, Lieskovsky G, et al. Emphysematous pyelonephritis: a 5-year experience with 13 patients. J Urol. 1985;134:1086–8. CrossRefPubMed Ahlering TE, Boyd SD, Hamilton CL, Bragin SD, Chandrasoma PT, Lieskovsky G, et al. Emphysematous pyelonephritis: a 5-year experience with 13 patients. J Urol. 1985;134:1086–8. CrossRefPubMed
7.
go back to reference Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology. 1996;198:433–8. CrossRefPubMed Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology. 1996;198:433–8. CrossRefPubMed
8.
go back to reference Soulen MC, Fishman EK, Goldman SM, Gatewood OM. Bacterial renal infection: role of CT. Radiology. 1989;171:703–7. CrossRefPubMed Soulen MC, Fishman EK, Goldman SM, Gatewood OM. Bacterial renal infection: role of CT. Radiology. 1989;171:703–7. CrossRefPubMed
9.
go back to reference Expert Panel on Urologic Imaging, Nikolaidis P, Dogra VS, Goldfarb S, Gore JL, Harvin HJ, Heilbrun ME, et al. ACR appropriateness Criteria® acute pyelonephritis. J Am Coll Radiol. 2018;15:S232–9. CrossRef Expert Panel on Urologic Imaging, Nikolaidis P, Dogra VS, Goldfarb S, Gore JL, Harvin HJ, Heilbrun ME, et al. ACR appropriateness Criteria® acute pyelonephritis. J Am Coll Radiol. 2018;15:S232–9. CrossRef
11.
go back to reference Owa S, Sasaki K, Yonemura S, Sakurai M. A case of emphysematous pyelonephritis after starting treatment for acute pyelonephritis. Hinyokika Kiyo. 2021;67:373–9. PubMed Owa S, Sasaki K, Yonemura S, Sakurai M. A case of emphysematous pyelonephritis after starting treatment for acute pyelonephritis. Hinyokika Kiyo. 2021;67:373–9. PubMed
12.
go back to reference Takei T, Hama Y, Ito T, Takemoto M. Emphysematous pyelonephritis detected incidentally by a second CT examination after the improvement of septic shock. Nihon Shuchu Chiryo Igakukai Zasshi. 2009;16:487–91. CrossRef Takei T, Hama Y, Ito T, Takemoto M. Emphysematous pyelonephritis detected incidentally by a second CT examination after the improvement of septic shock. Nihon Shuchu Chiryo Igakukai Zasshi. 2009;16:487–91. CrossRef
13.
go back to reference Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N’Dow J. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008;179:1844–9. CrossRefPubMed Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N’Dow J. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008;179:1844–9. CrossRefPubMed
14.
go back to reference Aboumarzouk OM, Hughes O, Narahari K, Coulthard R, Kynaston H, Chlosta P, et al. Emphysematous pyelonephritis: time for a management plan with an evidence-based approach. Arab J Urol. 2014;12:106–15. CrossRefPubMed Aboumarzouk OM, Hughes O, Narahari K, Coulthard R, Kynaston H, Chlosta P, et al. Emphysematous pyelonephritis: time for a management plan with an evidence-based approach. Arab J Urol. 2014;12:106–15. CrossRefPubMed
15.
go back to reference Adapala RR, Shetty R, Venugopal P, Prabhu GGL, Yalla D, Unnikrishnan B. Renal salvage, an achievable goal in patients with emphysematous pyelonephritis: outcomes of an algorithmic renal preserving strategy. Urol Ann. 2020;12:156–62. CrossRefPubMedPubMedCentral Adapala RR, Shetty R, Venugopal P, Prabhu GGL, Yalla D, Unnikrishnan B. Renal salvage, an achievable goal in patients with emphysematous pyelonephritis: outcomes of an algorithmic renal preserving strategy. Urol Ann. 2020;12:156–62. CrossRefPubMedPubMedCentral
17.
go back to reference Fisher A, Fralick M, Filion KB, Dell’Aniello S, Douros A, Tremblay E, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: a multi-site, prevalent new-user cohort study. Diabetes Obes Metab. 2020;22:1648–58. CrossRefPubMed Fisher A, Fralick M, Filion KB, Dell’Aniello S, Douros A, Tremblay E, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: a multi-site, prevalent new-user cohort study. Diabetes Obes Metab. 2020;22:1648–58. CrossRefPubMed
18.
go back to reference Tanvi P, Morgan C, Jesse H, Alamdeep K, Aliza L. Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a nationwide veterans health administration observational cohort study. Am J Cardiol. 2023;201:281–3. CrossRef Tanvi P, Morgan C, Jesse H, Alamdeep K, Aliza L. Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a nationwide veterans health administration observational cohort study. Am J Cardiol. 2023;201:281–3. CrossRef
19.
go back to reference Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171:248–56. CrossRefPubMedPubMedCentral Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171:248–56. CrossRefPubMedPubMedCentral
21.
go back to reference Sarah E, Christine L, Lindsay T. Evaluation of the safety and tolerability of sodium-glucose co-transporter 2 inhibitors in the older population: a systematic review. Sr Care Pharm. 2023;38:276–87. CrossRef Sarah E, Christine L, Lindsay T. Evaluation of the safety and tolerability of sodium-glucose co-transporter 2 inhibitors in the older population: a systematic review. Sr Care Pharm. 2023;38:276–87. CrossRef
22.
go back to reference Kufel WD, Scrimenti A, Steele JM. A case of septic shock due to Serratia marcescens pyelonephritis and bacteremia in a patient receiving empagliflozin. J Pharm Pract. 2017;30:672–5. CrossRefPubMed Kufel WD, Scrimenti A, Steele JM. A case of septic shock due to Serratia marcescens pyelonephritis and bacteremia in a patient receiving empagliflozin. J Pharm Pract. 2017;30:672–5. CrossRefPubMed
23.
go back to reference Woloshuk A, Lee M, Assmus M, Agarwal D, Krambeck A, Large T. A case of ureteral fungal mass removal in a patient taking empagliflozin. CEN Case Rep. 2021;10:603–7. CrossRefPubMedPubMedCentral Woloshuk A, Lee M, Assmus M, Agarwal D, Krambeck A, Large T. A case of ureteral fungal mass removal in a patient taking empagliflozin. CEN Case Rep. 2021;10:603–7. CrossRefPubMedPubMedCentral
24.
go back to reference Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79. CrossRefPubMed Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79. CrossRefPubMed
Metadata
Title
A case of emphysematous pyelonephritis in an older man with poorly controlled type 2 diabetes mellitus
Authors
Mayuka Nishikawara
Makoto Harada
Daiki Yamazaki
Tetsuji Kakegawa
Koji Hashimoto
Yuji Kamijo
Publication date
22-09-2023
Publisher
Springer Nature Singapore
Published in
CEN Case Reports
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-023-00821-7